Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB) today and set a price target of $30. The company’s shares closed yesterday at $15.59.
Yang noted:
“We see this development as incrementally positive for the company as Carsten brings a wealth of management experience, most recently serving as Bayer (BAYRY, not rated). The appointment is ahead of key asset SEL-212 entering into Phase III development. Current CEO Werner Cautreels, Ph.D., will continue to lead the company until December. The most important upcoming catalyst for Selecta remains the SEL-212 data readouts at the Rheumatology (ACR) 19-24, 2018.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 25.4% and a 55.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Selecta Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $35.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.02 and a one-year low of $7.95. Currently, Selecta Biosciences has an average volume of 136K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
